Does anticoagulation with edoxaban reduce cardiovascular death, stroke, or systemic embolism in patients with atrial high-rate episodes detected by implantable devices?
Patients with atrial high-rate episodes (AHREs) detected by implantable devices
Anticoagulation with edoxaban
Placebo
Composite of cardiovascular death, stroke, or systemic embolismcomposite
In patients with device-detected atrial high-rate episodes, routine anticoagulation with edoxaban did not reduce thromboembolic events but significantly increased the risk of major bleeding or death.
Among patients with AHREs detected by implantable devices, anticoagulation with edoxaban did not significantly reduce the incidence of a composite of cardiovascular death, stroke, or systemic embolism as compared with placebo, but it led to a higher incidence of a composite of death or major bleeding. The incidence of stroke was low in both groups. (Funded by the German Center for Cardiovascular Research and others; NOAH-AFNET 6 ClinicalTrials.gov number, NCT02618577; ISRCTN number, ISRCTN17309850.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Paulus Kirchhof
Tobias Toennis
Andreas Goette
New England Journal of Medicine
University of Oxford
University of Amsterdam
University of Birmingham
Building similarity graph...
Analyzing shared references across papers
Loading...
Kirchhof et al. (Fri,) studied this question.
www.synapsesocial.com/papers/69cbea344dc32b50d7af5e9e — DOI: https://doi.org/10.1056/nejmoa2303062